Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
10/29/2007
Trade Name:
Abilify
Generic or Proper Name (*):
aripiprazole
Indications Studied:
Schizophrenia
Therapeutic Category:
Antipsychotic
Ages Studied:
11- 17 years
Study #:
3
Study Type:
Efficacy/Safety
Study Design:
Single-Blind/Placebo/Parallel Group
No Patients:
302
No Centers:
101
No Countries:
13
BPCA(B), PREA(P):
B
Asian:
43
Black:
34
Other:
44
White:
180
Native Hawaiian or Pacific Islander:
1
American Indian/Alaska Native:
0
Hispanic/Latino:
41
Non-Hispanic/Non Latino:
261
-
-